AK129 + cadonilimab + oxaliplatin + capecitabine

AK129 + cadonilimab + oxaliplatin + capecitabine is an investigational combination therapy for cancer consisting of four agents: - **AK129**: An investigational drug, though publicly available data is limited regarding its mechanism; it is likely being evaluated as an anti-cancer agent. - **Cadonilimab**: A bispecific monoclonal antibody targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), functioning as an immune checkpoint inhibitor. It is developed to enhance anti-tumor immunity through synergistic checkpoint inhibition. Cadonilimab is approved in China for gastric cancer and is under investigation globally for use in combination regimens for various cancers, particularly gastrointestinal cancers[3][5]. - **Oxaliplatin**: A platinum-based chemotherapeutic agent (small molecule) that causes DNA crosslinking, inhibiting DNA synthesis and transcription, leading to apoptosis in cancer cells. Commonly used in gastrointestinal malignancies. - **Capecitabine**: An oral prodrug of 5-fluorouracil (5-FU) (small molecule antimetabolite) that inhibits DNA synthesis by interfering with thymidylate synthase, leading to cell death in rapidly dividing cells[2][6]. This combination is being explored primarily for the treatment of gastrointestinal cancers, such as gastric/gastroesophageal junction adenocarcinoma, with ongoing or recent phase II/III investigations focused on improving survival outcomes by leveraging the synergistic effects of immune checkpoint inhibition and cytotoxic chemotherapy[3][5].